From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – Prospective Recapitalisation Plans To Shaft Shareholders, Or Worse

By Nigel Somerville, the Deputy Sheriff of AIM | Monday 17 July 2023

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

AIM-listed crock Advanced Oncotherapy (AVO), currently suspended pending financial clarification and unable to produce its accounts, has announced prospective recapitalisation plans which include a death spiral, debt-for-equity conversions and a general shafting of the current equity holders. And the plans are clearly at an aspirational level, dependent as they are on new equity capital being made available, approval from the takeover panel, the agreement of creditors and shareholders too. The choice seems to be maybe almost death, or just death.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 11:28:39